S-1: Bio-Path Holdings Files for Public Offering Amidst Ongoing Clinical Trials

Bio-Path Holdings is seeking to raise capital through a public offering of common stock and warrants, while continuing to advance its clinical-stage oncology and obesity-focused drug candidates.

Summary

• Bio-Path Holdings, a clinical-stage biotech company, has filed a registration statement for a public offering of common stock, pre-funded warrants, and common warrants.
• The offering includes shares of common stock, pre-funded warrants to purchase common stock, Series A and B common warrants, and placement agent warrants.
• The company is developing four drug candidates using its DNAbilize technology, targeting various cancers and obesity.
• Prexigebersen, the lead drug candidate, is in a Phase 2 clinical trial for AML, with interim data showing promising results.
• BP1002, targeting Bcl-2, has completed Phase 1 monotherapy cohorts and is moving to a Phase 1b trial in combination with decitabine for AML.
• BP1003, targeting STAT3, is in IND-enabling studies for pancreatic cancer and NSCLC.
• BP1001-A, a modified version of prexigebersen, is in a Phase 1/1b trial for solid tumors and is being explored for obesity treatment.
• The company has faced challenges in meeting Nasdaq listing requirements, including minimum bid price and stockholders equity.
• The company has an accumulated deficit of $114.7 million and expects to incur further losses.
• The company's ability to continue as a going concern is dependent upon obtaining funding through one or more sources within the next 12 months.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive clinical trial results and a novel technology platform, the company's financial situation is precarious, with significant losses, a low cash balance, and potential delisting from Nasdaq. The need for additional capital and the going concern warning temper the positive aspects.

Positives

• Prexigebersen has shown promising interim results in a Phase 2 clinical trial for AML, with a 75% complete remission rate in newly diagnosed patients.
• BP1002 has completed Phase 1 monotherapy cohorts with no dose-limiting toxicities.
• BP1001-A has shown to enhance chemotherapy efficacy in preclinical solid tumor models.
• Preclinical work suggests BP1001-A could be a potential treatment for obesity in Type 2 diabetes patients.
• The company has a novel drug delivery technology called DNAbilize.

Negatives

• The company has incurred significant operating losses since its inception and expects to incur losses for the foreseeable future.
• The company has a cash balance of only $0.6 million as of September 30, 2024.
• The company has received a letter from Nasdaq indicating that it does not meet the minimum bid price requirement.
• The company has received a letter from Nasdaq indicating that it does not meet the minimum stockholders equity requirement.
• The company's ability to continue as a going concern is dependent upon obtaining funding through one or more sources within the next 12 months.

Risks

• The company has a history of operating losses and may never achieve profitability.
• The company will require substantial additional capital and may be forced to delay or eliminate drug development programs if unable to raise funds.
• The company faces intense competition from other pharmaceutical and biotechnology companies.
• The company must complete extensive clinical trials to demonstrate the safety and efficacy of its drug candidates.
• The company relies on third parties for manufacturing and clinical trials, which may cause delays.
• The company may not be able to obtain regulatory approval for its drug candidates.
• The company's common stock may be delisted from the Nasdaq Capital Market.
• The company's common stock is thinly traded and may be volatile.
• The company may experience dilution to existing stockholders from future equity offerings.

Future Outlook

The company expects to continue to incur significant operating losses and will require substantial additional capital to fund its operations. The company plans to pursue FDA expedited programs for Fast Track designation for prexigebersen and is evaluating whether to seek to expand Stage 2 of the Phase 2 clinical trial in Europe. The company anticipates initiating a first-in-human Phase 1 clinical trial for BP1001-A in 2025 to further validate safety, measure pharmacokinetics and establish dosing for potential pivotal trials for obesity.

Management Comments

• Management has determined that it can reduce spending on its day-to-day operations, sell laboratory assets and temporarily delay planned activities if needed.
• Management estimates that it will receive net proceeds of approximately $ million from the sale of the securities offered by us in this offering.

Industry Context

The pharmaceutical and biotechnology industry is highly competitive, with many companies developing treatments for similar indications. The company faces competition from entities with greater resources and experience. The company is developing novel treatments and technology platforms based on modalities and technology that may be similar to others.

Comparison to Industry Standards

• The company's lead drug candidate, prexigebersen, is being developed for AML, a disease with several approved treatments, including venetoclax in combination with LDAC, decitabine or azacytidine.
• The company's Phase 2 clinical trial for prexigebersen is being conducted in combination with decitabine and venetoclax, which is a common treatment approach for AML.
• The company's BP1002 drug candidate is targeting Bcl-2, a protein that is also targeted by venetoclax, a drug approved for CLL and AML.
• The company's BP1003 drug candidate is targeting STAT3, a protein that is also being targeted by other companies, including Ionis Pharmaceuticals, Inc.
• The company's BP1001-A drug candidate is being developed for solid tumors, including ovarian and endometrial cancer, which are areas with high unmet medical needs.

Stakeholder Impact

• Shareholders will experience immediate and substantial dilution in the net tangible book value per share of the common stock they purchase.
• Shareholders may experience future dilution as a result of future equity offerings or other equity issuances.
• Shareholders may be unable to sell their common stock at or near their asking prices or at all.
• The company's common stock may be delisted from the Nasdaq Capital Market, which could negatively impact the price of the common stock and the ability to access the capital markets.
• The company does not anticipate paying cash dividends, and accordingly stockholders must rely on stock appreciation for any return on their investment.
• The company's management is required to devote substantial time and incur additional expense to comply with public company regulations.

Next Steps

• The company plans to continue enrollment in the Phase 2 clinical trial for prexigebersen.
• The company plans to advance to the next planned higher dose of 90 mg/m2 in the BP1002 Phase 1/1b clinical trial in the first quarter of 2025.
• The company plans to complete the additional IND enabling study for BP1003 and file an IND application.
• The company plans to complete enrollment in the second dose cohort of BP1001-A in the first quarter of 2025.
• The company plans to initiate a first-in-human Phase 1 clinical trial for BP1001-A in 2025 to further validate safety, measure pharmacokinetics and establish dosing for potential pivotal trials for obesity.
• The company plans to pursue FDA expedited programs for Fast Track designation for prexigebersen.
• The company is evaluating whether to seek to expand Stage 2 of the Phase 2 clinical trial in Europe.
• The company intends to continue to monitor the closing bid price of its common stock and may consider implementing available options to regain compliance with the Minimum Bid Price Rule, including by effecting a reverse stock split.
• The company intends to continue making efforts to regain compliance with the Stockholders Equity Requirement.

Key Dates

Keywords

RNAi, nanoparticle, oncology, obesity, DNAbilize, prexigebersen, AML, Bcl-2, STAT3, clinical trials, drug development, biotechnology, warrants, public offering